Review : Modulation of experimental systemic lupus erythematosus with linomide

Abstract

Objective. The objective of this study was to assess the beneficial effects of an early adminis tration of low dose linomide, a new immunomodulator, in an animal model of experimental systemic lupus erythematosus (SLE).

Methods. Experimental SLE was induced in naive BALB/c mice, by immunization with anti-DNA mAb (MIV-7). Control Mice immunized with irrelevant human IgM served as controls. The immunized mice were treated with linomide (0.1 mg/ml in the drinking water), four weeks prior to the first immunization, at an early stage of the disease induction (one month after boost injection), or at a later stage (3 months following boost immunization). The treatment duration was 3 months in all schedules. The follow-up studies continued for 8 weeks after discontinuation of the treatment.

The presence in the serum of autoantibodies against ssDNA, dsDNA, histones, phospho lipids and an irrelevant autoantigen - pyruvate dehydrogenase, was determined by enzyme- linked immunosorbent assay (ELISA). The clinical parameters assessed included erythrocyte sedimentation rate, peripheral blood cell counts and proteinuria.

Results. There was a 50-64% decrease in autoantibody levels in the sera of mice immunized with anti-DNA (MIV-7) mAb at the early stage of experimental SLE in mice which received linomide for a period of 3 months. No effect of linomide was noted in mice which received the drug during the later stages of experimental SLE when the disease was fully developed. Linomide had a preventive effect on the induction of experimental SLE in naive mice, when the treatment was initiated before the induction of the disease. This effect was abolished following cessation of the treatment.

Conclusions. Linomide proved to be effective at the early stages of induction of the experi mental SLE. However, the autoantibody levels rose following discontinuation of the therapy.

Keywords

anti-DNA antibodies SLE linomide autoimmunity autoantibodies

Get full access to this article

View all access options for this article.

References

Mendlovic S. , Brocke S. , Shoenfeld Y. , Ben-Bassat M. , Meshorer A. , Bakimer R. , Mozes E. Induction of a SLE like disease in mice by a common anti DNA idiotype. Proc Natl Acad Sci USA 1988; 85: 2260-2264.

Tincani A. , Balesterieri G. , Allergri F. , Cattaneo R. , Fornasasieri A. , Sinico A. , D'Amico G. Induction of experimental SLE in naive mice by immunization with human polyclonal anti DNA antibody carrying the 16/6 idiotype. Clin Exp Rheumatol 1993; 11: 129-134.

Dang H. , Noriyoshi O. , Takei M. , Lazaridis K. , Talal N. Induction of lupus associated autoantibodies by immunization with native and recombinant Ig polypeptides expressing a cross reactive idiotype 4B4. J Immunol 1993; 151: 7260-7267.

Shoenfeld Y. Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J 1994 ; 8: 1296-1301.

Blank M. , Krup M. , Mendlovic S. , Fricke H. , Mozes E. , Talal N. , Coates Arm , Shoenfled Y. The importance of the pathogenic 16/6 idiotype in the induction of SLE in naive mice. Scand J Immunol 1990; 31: 45-52.

Blank M. , Mendlovic S. , Mozes E. , Shoenfeld Y. Induction of SLE like disease in naive mice with a monoclonal anti-DNA antibody derived from a patient with polymyositis carrying 16/6 Id. J Autoimmun 1988; 1: 683-689.

Blank M. , Mendlovic S. , Mozes E. , Coates Arm , Shoenfeld Y. Induction of systemic lupus erythematosus in naive mice with T cell lines specific for human anti-DNA antibody SA-1 (16/6 Id + ) and for mouse tuberculosis antibody, TB/68 (16/6 Id + ). Clin Immunol Immunopathol 1991; 60: 471-473.

Blank M. , Mendlovic S. , Fricke H. , Mozes E. , Talal N. , Shoenfeld Y. Sex hormones involvement in induction of experimental SLE by a pathogenic and DNA idiotype in naive mice. J Rheumatol 1990; 17: 311-317.

Blank M. , Ben-Bassat M. , Shoenfeld Y. The effect of cyclosporin A on early and late stages of experimental lupus . Arthritis Rheum 1992; 35: 1350-1355.

10.

Blank M. , Sredni B. , Albeck M. , Mozes E. , Shoenfeld Y. The effect of the immunomodulator agent AS101 on interleukin 2 production in systemic lupus erythematosus (SLE) induced in mice by a pathogenic anti-DNA antibody. Clin Exp Immunol 1990; 79: 443-447.

11.

Blank M. , Manosroi J. , Momer Y. , Manosroi A. , Kopolovic J. , Charcon-Polak S. , Shoenfeld Y. Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate. Clin Exp Immunol 1994; 98: 434-441.

12.

Tomer Y. , Blank M. , Shoenfeld Y. Suppression of experimental antiphospholipid syndrome and systemic lupus erythematosus in mice by anti-CD4 monoclonal antibodies. Arthritis Rheum 1994; 37: 1236-1244.

13.

Krause I. , Blank M. , Kopolovic J. , Afek A. , Goldberg I. , Tomer Y. , Shoenfeld Y. Abrogation of experimental lupus erythematosus and primary antiphospholipid syndrome with intravenous gammaglobulin. Clin Immunol Immunopathol 1995; 77: 229-235.

14.

Blank M. , Krause I. , Buskila D. , Teitelbaum D. , Kopilovic J. , Afec A. , Goldberg I. , Shoenfeld Y. Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of non-specific T-suppressor cells. Cell Immunol 1995; 162: 114-122.

15.

Blank M. , Ben-Bassat M. , Shoenfeld Y. Modulation of SLE induction in naive mice by specific T cells with suppressor activity to pathogenic anti-DNA idiotype. Cell Immunol 1991; 137: 1-13.

16.

Stalhandske T. , Eriksson E. , Sandberg BM

A novel quinolincarboxamide with interesting immunomodulating activity. Int

J Immunopharmacol 1982; 4: 336.

17.

Kalland T. , Alm G. , Stalhandske T. Augmentation of mouse natural killer activity by LS-2616, a new immunomodulator . J Immunol 1985; 134: 3956-3961.

18.

Kalland T. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J Immunol 1990; 144: 4472-4476.

19.

Karussis DM , Lehmann D. , Slavin S. , Kalland T. , Vourka-Karussis U. , Mizrachi-Koll R. , Ovadia H. , Abramsky O. Immunomodulation of autoimmunity by linomide. Isr J Med Sci 1995; 31: 38-41.

20.

Gonzalo JA , Gonzalez-Garcia A. , Kalland T. , Hedlung G. , Martinez C. , Kroemer G. Linomide inhibits programmed cell death of peripheral T-cells in vivo . Eur J Immunol 1994; 24: 48-52.

21.

Vukanovic J. , Hartley-Asp B. , Isaacs JT Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. Prostate 1995; 26: 235-246.

22.

Vulkanovic J. , Isaacs JT Linomide inhibits angiogenesis, growth, metastasis and macrophage infiltration within rat prostatic cancers . Cancer Res 1995; 55: 1499-1504.

23.

Karussis DM , Lehmann D. , Slavin S. , Vourka-Karussis U. , Mizrachi-Koll R. , Ovadia H. , Ben-Nun A, Kalland T, Abramsky O. Inhibition of acute experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol 1993; 34: 654-660.

24.

Karussis DM , Slavin S. , Lehmann D. , Vourka-Karussis U. , Mizrachi-Koll R. , Ovadia H. , Kalland T. , Abramsky O. Successful treatment of chronic-relapsing experimental autoimmune encephalomyelitis with linomide (LS-2616), a synthetic immunomodulator. Proc Natl Acad Sci USA 1993; 90: 6400-6404.

25.

Tarkowski A. , Gunnarsson K. , Nilsson LA , Lindholm L. , Stalhndske T. Successful treatment of autoimmunity in MRL/lpr mice with LS-2616, a new immunomodulator . Arthritis Rheum 1986; 29: 1405-1408.

26.

Tarkowski A. , Gunnarsson K. , Stalhandske T. Effects of LS-2626 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice. Immunology 1986; 59: 589-594.

27.

Spetz-Hagberg AL , Goldschmidt TJ , Stalhandske T. et al. Amelioration of intrathymic T cell development and peripheral T cell reactivities in autoimmune mice undergoing therapy with a novel immunomodulator. Int Immunol 1990; 2: 645-650.

28.

Bjork J. , Kleinau S. Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice. Agents Actions 1989 ; 27: 319-321.

29.

Slavin S. , Sidi H. , Weiss L. , Rosenman E. , Kalland T. , Gross D. Linomide, a new treatment for autoimmune diseases: the potential in type I diabetes. Diabetes Metab Rev 1993; 9(4): 311-315.

30.

Gross DJ , Sidi H. , Weiss L. , Kalland T. , Rosenmann E. , Slavin S. Prevention of diabetes mellitus in non-obese mice by linomide, a novel immunomodulating drug. Diabetologia 1994; 37: 1195-1201.

31.

Blank M. , Krause I. , Ben-Bassat M. , Shoenfeld Y. Induction of experimental antiphospholipid syndrome associated with SLE following immunization with human monoclonal pathogenic anti-DNA idiotype . J Autoimmun 1992; 5: 1-15.

32.

Blank M. , Smorodinsky N. , Keydar I. , Chaitchik S. , Shoenfeld Y. The production of human monoclonal anti-MMTV antibodies by in vitro immunization with anti-idiotypic antibodies. Immunol Lett 1991;28:65-72.

33.

Zurgil N. , Bakimer R. , Moutsopoulos M. , Tzioufas AG , Youinou P. , Isenberg DA , Scheinberg M. , Kveder T. , Rozman B. , Luderschmidt C. , Meroni PL , Kaplan MM , Shoenfeld Y. Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. J Clin Immunol 1992; 12: 201-209.

34.

Shoenfeld Y. , Segal O. , Segal O. et al. Detection of antibodies to total histones and their asymptomatic relatives. Arthritis Rheum 1987; 30: 169-175.